Chieh Yu Liu
Chieh Yu Liu @chiehyuliu

Performance
All

13.95%2026
2026
-10.74%2025
2025
32.25%2024
2024
14.38%2023
2023
-20.21%2022
2022
15.32%2021
2021
-1.73%2020
2020
-9.68%2019
2019
32.3%0%-32.3%
Discussions
Chieh Yu Liu
@chiehyuliu
Bought $TSM @205.44
Taiwan
2y
I've just opened a position using 1.06% of my equity.
Not investment advice. The author may have financial interests in the mentioned instruments.
TSM
Taiwan Semiconductor Manufacturing Co Ltd - ADR
472.78
13.58 (2.96%)
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
I took a deeper look at my portfolio and reviewed my dividend strategy as follows: This dividend-focused strategy offers a blend of income generation and potential capital appreciation. The portfolio's 1.20% dividend yield provides a steady income stream, enhanced by monthly payouts for consistent... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
My significant investment in Amazon (AMZN), comprising 34.51% of my portfolio, is driven by its multifaceted strengths and future growth potential. Amazon's #2 ranking on the Forbes 500 underscores its market leadership, while the enduring nature of e-commerce, particularly for essential goods,... Show More
Agree with my POV
100.00%
Disagree and comment below
100.00%
0 Votes
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
I reviewed my portfolio and here’s what I think how it has been and is performing so far. Feel free to check out my portfolio. It is currently valued at $44,015.46, reflects a strategic and diversified approach across 12 carefully selected holdings. While I'm maintaining a steady position today,... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
TSMC (TSM) is a critical player in the semiconductor industry, holding a near-monopoly on advanced chip manufacturing. This gives them a strong competitive advantage. The increasing demand for high-performance computing, AI, and 5G technology fuels their growth. However, geopolitical risks, particularly... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
AbbVie (ABBV) faces a period of transition. While Humira biosimilar competition is impacting revenue, AbbVie's diverse portfolio, including newer drugs like Rinvoq and Skyrizi, offers growth potential. Strong performance in other therapeutic areas and strategic acquisitions are helping to offset... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
Lockheed Martin's stock (LMT) presents a mixed outlook. The company benefits from consistent government defense spending, providing a stable revenue stream. Recent geopolitical tensions further bolster demand for their advanced military technology, including the F-35 fighter jet. However, potential... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
The reason why I stopped investing in Bitcoin few years back is because of its extreme volatility and the lack of clear regulatory oversight. These factors created an unpredictable and potentially risky environment. While the technology behind it is fascinating, I prefer investments with more stability... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
Stock Analysis 2025-1-11 Google's stock price has been volatile in recent months, reflecting a mix of positive and negative developments. On the positive side, the company has shown strong growth in its cloud computing business, which is seen as a key driver of future revenue. Additionally, Google's... Show More
Chieh Yu Liu
@chiehyuliu
Taiwan
2y
Here’s the stock market outlook for the next 3 months. Market temperature: Yellow light (mixed sentiment) Opportunities: Potential for Growth **AI-driven Innovation:** Continued advancements in Artificial Intelligence (AI) are expected to fuel growth in technology sectors, particularly those involved... Show More
Optimistic
100.00%
Watching
100.00%
Concerning
100.00%
0 Votes

About Chieh Yu Liu
Taiwan
Strategy: Value

Goal: 85% long-term + 15% short-term
Show Full Bio Translate
1 Copiers
95 Followers

Similar Traders